FY2024 EPS Estimate for Sage Therapeutics Raised by Analyst

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Stock analysts at Wedbush lifted their FY2024 earnings per share (EPS) estimates for shares of Sage Therapeutics in a research report issued to clients and investors on Wednesday, October 30th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post earnings of ($7.06) per share for the year, up from their previous forecast of ($7.20). Wedbush has a “Neutral” rating and a $8.00 price target on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.43) per share. Wedbush also issued estimates for Sage Therapeutics’ Q4 2024 earnings at ($2.03) EPS, Q2 2025 earnings at ($1.21) EPS, Q3 2025 earnings at ($1.23) EPS, Q4 2025 earnings at ($1.23) EPS and FY2025 earnings at ($5.04) EPS.

Other equities analysts have also recently issued reports about the company. Raymond James reaffirmed a “market perform” rating on shares of Sage Therapeutics in a report on Thursday, October 10th. Piper Sandler reaffirmed an “overweight” rating and issued a $26.00 price objective (down from $52.00) on shares of Sage Therapeutics in a report on Wednesday. HC Wainwright dropped their price objective on Sage Therapeutics from $25.00 to $14.00 and set a “neutral” rating for the company in a report on Wednesday. JPMorgan Chase & Co. lowered their price target on Sage Therapeutics from $12.00 to $10.00 and set a “neutral” rating for the company in a report on Tuesday, August 6th. Finally, Truist Financial lowered their price target on Sage Therapeutics from $13.00 to $8.00 and set a “hold” rating for the company in a report on Wednesday. Three research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have assigned a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $12.89.

Sage Therapeutics Price Performance

Shares of NASDAQ SAGE opened at $6.05 on Friday. The stock has a market capitalization of $370.10 million, a PE ratio of -1.08 and a beta of 0.91. The business has a fifty day moving average price of $7.44 and a two-hundred day moving average price of $9.95. Sage Therapeutics has a fifty-two week low of $5.84 and a fifty-two week high of $28.26.

Sage Therapeutics (NASDAQ:SAGE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The firm had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The business’s revenue for the quarter was up 337.1% compared to the same quarter last year. During the same quarter last year, the firm earned ($2.81) earnings per share.

Institutional Investors Weigh In On Sage Therapeutics

Institutional investors have recently made changes to their positions in the stock. Headlands Technologies LLC boosted its position in shares of Sage Therapeutics by 245.3% during the 2nd quarter. Headlands Technologies LLC now owns 3,916 shares of the biopharmaceutical company’s stock valued at $43,000 after purchasing an additional 2,782 shares in the last quarter. Lazard Asset Management LLC bought a new stake in shares of Sage Therapeutics during the 1st quarter valued at about $127,000. Virtu Financial LLC bought a new stake in shares of Sage Therapeutics during the 1st quarter valued at about $187,000. China Universal Asset Management Co. Ltd. boosted its position in shares of Sage Therapeutics by 66.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 11,742 shares of the biopharmaceutical company’s stock valued at $85,000 after purchasing an additional 4,672 shares in the last quarter. Finally, Quest Partners LLC boosted its position in shares of Sage Therapeutics by 14.5% during the 2nd quarter. Quest Partners LLC now owns 11,763 shares of the biopharmaceutical company’s stock valued at $128,000 after purchasing an additional 1,486 shares in the last quarter. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics Company Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.